Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 322 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors January 28, 2025 FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum April 13, 2022 Load more HOT NEWS A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... Scientists reveal how air pollution can cause lung cancer in people...
